Munich Cluster for Systems Neurology
print


Breadcrumb Navigation


Content

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.

J Alzheimers Dis. 2019 Mar 18. doi: 10.3233/JAD-181088. [Epub ahead of print]

Authors/Editors: Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, Papanastasiou AD, Grimmer T, Gourzis P, Berthele A, Hemmer B. Kübler H, Martin J, Politis A, Perneczky R.
Publication Date: 2019

04_alexopoulos

Abstract

Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

Related Links